Indaba Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
+$1.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRHC
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
|
+$67.2M |
| 2 |
Capri Holdings
CPRI
|
+$17.9M |
| 3 |
Blue Owl Capital
OBDC
|
+$2.51M |
| 4 |
ALLG.WS
Allego N.V. Warrants
ALLG.WS
|
+$31.5K |
| 5 |
Rigetti Computing Warrants
RGTIW
|
+$15.6K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.09% |
| 2 | Healthcare | 11.17% |
| 3 | Financials | 0.78% |
| 4 | Consumer Discretionary | 0% |
| 5 | Industrials | 0% |
Similar funds
Indaba Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Indaba Capital Management held 17 positions worth $174M, down 49% from $339M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Indaba Capital Management withdrew a net $170M in Q4 2023, closing 8 positions and reducing 1 holding. Its most notable exit was Tabula Rasa HealthCare, Inc. Common Stock, an estimated $67.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Indaba Capital Management added an estimated $1.1M to Merrimack Pharmaceuticals, Inc..
- Indaba Capital Management added most to Merrimack Pharmaceuticals, Inc. in Q4 2023, an estimated $1.1M increase.
- Indaba Capital Management's biggest Q4 2023 reduction was Blue Owl Capital, cutting an estimated $2.51M.
- Indaba Capital Management fully exited Tabula Rasa HealthCare, Inc. Common Stock in Q4 2023, selling an estimated $67.2M.
- Indaba Capital Management's ten largest holdings make up 100% of its $174M portfolio in Q4 2023.
- Indaba Capital Management opened 0 new positions and closed 8 in Q4 2023.
- Indaba Capital Management's portfolio value fell 49% quarter-over-quarter to $174M.
Based on Indaba Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.